Stay updated with breaking news from Servier Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- TIBSOVO is an inhibitor of the mutated isocitrate dehydrogenase-1(IDH1) enzyme -- TIBSOVO is the first...
PARIS, Jan. 18, 2022 /PRNewswire/ -- Servier, an independent global pharmaceutical group, published its results for the 2020/21 financial year, en...
/PRNewswire/ -- Servier, an independent global pharmaceutical group, published its results for the 2020/21 financial year, ending on September 30, 2021, and...
/PRNewswire/ -- Servier, an independent global pharmaceutical group, published its results for the 2020/21 financial year, ending on September 30, 2021, and...
- Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current